Bioorganic & Medicinal Chemistry 21 (2013) 4051–4057

Contents lists available at SciVerse ScienceDirect

Bioorganic & Medicinal Chemistry

journal homepage: www.elsevier.com/locate/bmc

Plucking the high hanging fruit: A systematic approach for targeting protein–protein interactions

Monika Raj, Brooke N. Bullock, Paramjit S. Arora *

Department of Chemistry, New York University, NY 10003, USA

ARTICLE INFO

Article history:
Available online 4 December 2012

Keywords:
Protein–protein interactions
Secondary structure mimics
Computational design
Hot spot residues
Rational design

ABSTRACT

Development of specific ligands for protein targets that help decode the complexities of protein–protein interaction networks is a key goal for the field of chemical biology. Despite the emergence of powerful in silico and experimental high-throughput screening strategies, the discovery of synthetic ligands that selectively modulate protein–protein interactions remains a challenge for bioorganic and medicinal chemists. This Perspective discusses emerging principles for the rational design of PPI inhibitors. Fundamentally, the approach seeks to adapt nature's protein recognition principles for the design of suitable secondary structure mimetics.

1. Introduction

Protein–protein interactions (PPIs) are attractive targets for therapeutic intervention because of their fundamental roles in vital biological processes including gene expression, cell growth, proliferation, nutrient uptake, morphology, motility, intercellular communication and apoptosis. The past decade has seen emerging methods to inhibit these complexes, which have traditionally been termed 'undruggable'. Although it is early to say if inhibition of PPIs will become a routine strategy for drug design, preliminary success in the field provides guidelines for the types of interfaces that may be amenable to disruption by synthetic compounds.[1–4] Pharmaceutical chemists often gravitate toward design of enzyme inhibitors as drug candidates—enzymes as a class constitute roughly half of drug targets.[5] Enzymes are appealing targets for a list of reasons: (1) they serve as critical levers for biological functions, (2) nature offers small molecules that may be used as templates for further manipulation,[6] (3) mechanism-based inhibitors may be rationally designed,[7] and (4) enzyme pockets are often appropriately sized for small molecules.[8,9] The largely flat and pocket-less protein interfaces lack several of these features but are fascinating both because of basic challenges associated with molecular design and for the prospect of exploring relatively uncharted biology for therapeutic intervention.

2. A secondary structure-centric view of protein interfaces

The Protein Data Bank, with roughly 10,000 entries of multiprotein complexes, provides a treasure of illustrations to unravel the rules nature employs to bring protein partners together (Fig. 1). One approach for the design of synthetic inhibitors is based on mimicry of protein subdomains to interfere with these complex formations.[4,10–13] A second successful method utilizes computational and experimental high-throughput and fragment-based screening strategies to locate small molecule fragments that stick to protein surfaces.[14–19] Strategies that afford scaffolds for PPIs based on natural products and natural product like molecules,[20] peptide macrocycles[21] and phage display-based miniproteins[22–24] have also led to significant success. Although, PPIs cover large surface areas, often, a small subset of residues (termed 'hot spot residues') contributes significantly to the binding free energy.[25–28] An analysis of PPIs, which have been successfully inhibited by small molecules, suggests that a category of PPIs contains features that approximate enzyme active sites, that is, they contain an array of hot spot residues clustered within relatively small radii.[27–29] With this viewpoint, we and others have assessed the dataset in the PDB[30] to identify the subset of PPIs that can be potential targets for small molecules, and those that would require larger molecules.[4,31–34] Several computational strategies to define *pockets* on protein–protein interfaces for drug design have been outlined.[4,35–39] Our approach has centered on the role of secondary structures in mediating protein–protein interactions.[40] A key advantage of the protein secondary structure mimetic strategy is that the array of side chain residues along a conformationally defined backbone facilitates molecular design. A second advantage is that direct mimics of protein secondary structures provide medium-sized molecules, which may potentially target the chosen protein with high affinity and specificity.

A basic challenge associated with this secondary structure-centric approach involves dissection of the energetic contribution of the specific secondary structure to the protein–protein complex.

* Corresponding author.
E-mail address: arora@nyu.edu (P.S. Arora).

0968-0896/$ - see front matter © 2012 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.bmc.2012.11.023



Figure 1. Protein–protein interactions are often mediated by secondary structures: (a) α-helical and (b) β-sheet interfaces from barnase_barstar (PDB code: 1BGS) and Raf-Rap (PDB code: 1GUA), respectively.

Three related questions include: (1) what is the minimum proportion of the free energy of binding that must reside on the secondary structure for its mimetic to retain inhibitory activity? (2) Are there interfaces that are naturally more suited for small mimics of target protein secondary structures and those that would require larger mimics? (3) How small can the mimetic be made to procure the 'drug like' properties linked to small molecules while retaining specificity associated with larger molecules? We have undertaken computational efforts to probe these questions and have begun to experimentally evaluate hypotheses emerging from these studies.

Our initial analysis has focused on PPIs that feature helices at interfaces, although the approach can be extended to other motifs. Targeting of α-helical interfaces offers several basic advantages: α-helices constitute the largest class of protein secondary structures—roughly 60% of protein–protein interactions in the current PDB contain helices at interfaces.[31] And, helices are often easier to mimic than other secondary structures such as β-strands, which tend to aggregate; although, there has been significant progress in the design of β-strand mimics.[41–48] Importantly, stable mimics of interfacial helices have been shown to be useful as potential leads for drug design.[11,49–55]

In this Perspective, we discuss structural attributes of PPIs that our group uses to initiate design of either small molecule helix mimetics[56–60] or stabilized peptide helices.[10,13,61–63] Some interfaces may be targeted by either strategy. Stabilized peptide helices utilize constraints to order the peptide backbone while small molecule or nonpeptidic helix mimetics array the critical peptide side chain functional groups on a synthetic scaffold.[13] On the basis of spatial arrangement of hotspot residues at the interface, revealed by alanine scanning mutagenesis data,[64,65] we classified PPIs as *binding clefts* or *extended interfaces* (Fig. 2).[31] Receptors with clefts are targeted by helices with two or more hot spot residues within a 7 Å radius, while the extended interfaces category features a distribution of hot spot residues over a larger distance of 7–30 Å. Camacho and coworkers recently suggested that a combination of computed change in solvent accessible surface areas (ΔSASA) and energy scores may be a better gauge of hot spot residues than alanine scans alone.[33] For alanine mutagenesis scans, the ΔΔG value refers to the change in free energy when a residue is mutated to alanine, thus a positive value indicates that mutation to alanine decreases the affinity of PPI and wild type residue contributes to binding. For interfacial residues, the ΔSASA of a residue is calculated by subtracting the SASA of the residue in the PPI complex from the SASA of the individual residue without any partner protein chains, and a positive value indicates that the residue is buried in the PPI complex and less accessible to solvent. Rosetta[29,65] and PocketQuery[66] offer easily accessible resources for such computational analyses.

We hypothesized that a single turn of the α-helix approximates the distance traversed by typical small drug candidates,[39] that is, Lipinski's 'rules of five' compliant molecules.[67,68] Indeed, the classical small molecule inhibitors of PPIs—notably the nutlin family compounds developed by Roche to target the p53/Hdm2 complex—are mimics of residues that span one helical turn.[69,70] The high density of hot spot residues in *binding clefts* evoke array of functionality in enzymatic pockets. Based on this analysis, we postulate that *binding clefts* may be targetable by small molecule or nonpeptidic helix mimetics; however, *extended interfaces* that feature hot spot residues spanning a much larger number of helical turns will likely require medium to large sized molecules such as stabilized peptide helices for specific inhibition.[31] Although, these larger inhibitors will not fit the mold of canonical 'drug-like' molecules, emerging evidence suggests that macrocycles and other discretely folded molecules may translocate to target intracellular interactions.[71–73]

We further classified interfacial interactions as potentially capable of leading to 'high affinity' inhibitors if the average experimental/computed $\Delta\Delta G_{avg}$ for alanine mutagenesis of 2–4 hot spot



Figure 2. Helical interfaces can be divided between those that feature *clefts* for binding and those with *extended interfaces*. The cleft interfaces may be compared to enzyme pockets in that a high density of important contacts is concentrated in a small region. The Gleevek/tyrosine kinase (PDB code: 1XBB), p53/MDM2 (PDB code: 1YCR) and cyclin-dependent kinase6/D-type viral cyclin (PDB code: 1G3N) complexes are representative examples of enzyme pockets, binding cleft and extended interfaces, respectively.

Table 1
Classification of helical protein interfaces

Types of PPIs	PDB code, helix sequence	Arrangement of hot spot residues on the target helix	ΔΔG[a] (kcal/mol)	ΔSASA[b]	Known inhibitors	Protein names Function
Interfaces with binding clefts						
		*i*	3.8	131.1	1. Small molecules[70,77]	MDM2 (gray): coactivator.
	1YCR	*i* + 4	4.4	136.7	2. Helix mimetics[59,60,80,101–105]	p53 (green): transcriptional activator.
	[19]FSDLWKLLPE[28]	*i* + 7	2.0	73.4		Function:Apoptotic signaling, cell-cycle arrest.
		(Avg)	(3.4)	(113.7)		
		i	4.2	168.3	1. Linear peptide[106]	Gia1 (gray): Guanine nucleotide-binding
	1Y3A	i + 3	3.3	93.9		protein alpha-1 subunit
	[5]WYDFLM[10]	*i* + 4	1.8	83.8	2. Cyclic peptides[107]	KB752 (green): peptide Function: Signaling protein
		(Avg)	(3.1)	(115.3)		
		i	2.7	102.2		
	1BXL	*i* + 3	2.2	87.3	1. Small molecules[82,108–110]	BCL-XL (gray):
	[578]LAIIGDDI[585]	*i* + 7	1.2	79.3	2. Helix mimetics[50,111–113]	BAK peptide (green):
		(Avg)	(2.0)	(89.6)		Function: apoptosis
		i	2.9	122.1		CDK2(gray): cyclin dependent kinase-2
	1JSU	*i* + 1	4.9	116.8	1. Small molecules[114,115]	P27(KIP1): kinase
	[85]PEFYYR[90]	*i* + 3	1.1	64.6		inhibitor (blue, helix in green)
		(Avg)	(3.0)	(101.2)		Function: Enzyme Kinase
		i	2.8	160.69		

(*continued on next page*)

Table 1 (*continued*)

Types of PPIs	PDB code, helix sequence	Arrangement of hot spot residues on the target helix	ΔΔG[a] (kcal/mol)	ΔSASA[b]	Known inhibitors	Protein names Function
Extended helical interfaces						
	1AIK	*i* + 3	1.92	124.62	1. Small molecules[116,117]	HR1 (gray): N-terminal heptad repeat of HIV-1 GP41
[628]WMEWDREINNYTSLI[642]	*i* + 10	2.01	77.32	2. Linear	peptide[91] and helix mimetics[53,55,91–94]	HR2 (green): C-terminal heptad repeat of HIV-1 GP-41
		i + 14	1.76	92.59		Function: glycoprotein
		(Avg)	(2.12)	(113.8)		Ca2+-CaM (gray): calmodulin
	3BXK	*i*	1.9	130.49		
[196]1IYAAMMIMEYYRQS1[974]	*i* + 1	1.6	105.38			
		i + 4	1.0	104.8		Cav 2.1 IQ (green): voltage gated calcium channels-Isoleucine-glutamine
		i + 6	3.1	111.97	No known inhibitors	
		i + 10	2.7	103.28		
		i + 11	2.0	107.88		Function: Signaling protein
		(Avg)	(2.05)	(110.6)		
	1NVW	i	1.64	43.73	1. Small molecule[99,100]	Ras (gray): guanine nucleotide binding protein
[930]FGIYLTNILKTEEGN[944]	*i* + 6	1.11	57.75		Sos (blue, helix in green): Ras-specific guanine	
		i + 13	1.10	57.98		nucleotide exchange factor
		i + 15	2.35	67.70	2. Helix mimetics[52]	Function: signaling protein
		(Avg)	(1.55)	(56.79)		
w 	1K90	*i*	0.71	78.71		
	[82]EEEIREAFRVFDK[94]	*i* + 3	1.99	90.67	No known inhibitors	EF(gray): Edema factor
		i + 6	1.84	105.7		
		i + 7	1.26	81.14		Calmodulin (blue, helix in green):
		i + 10	1.53	64.99		Function: Anthrax Toxin
		(Avg)	(1.47)	(84.24)		

[a] Calculated using computational alanine scanning suite of Rosetta.[65]
[b] Obtained from PocketQuery.[33,66] Numbers in parentheses refer to average of ΔΔG or ΔSASA values for hot spot residues.

residues is $\geqslant$2 kcal/mol. These empirically derived values emerge from the analysis of known small molecule inhibitors of PPIs, as described previously.[31] We predict that if the $\Delta\Delta G$ for alanine substitution of wild-type hot spot residues is <<2 kcal/mol, inhibitors based on wild-type sequence may bind the target protein with a low affinity (i.e., with dissociation constants in the micromolar range). However, this analysis only considers natural interactions and wild-type residues; use of non-natural residues may provide higher affinity leads. Furthermore, these predictions are based on high-resolution structures of multi-protein complexes and do not account for protein dynamics. Nevertheless, use of these rubrics has provided a starting point for the rational design of new classes of protein–protein interaction inhibitors.[52,74] Below, we discuss specific examples of protein complexes where the secondary structure-centric approach has been or could be applied to discover inhibitors.

3. Classification of helical protein interfaces

3.1. Binding clefts

This category of PPIs contains a *cleft* for helical residues, that we predict are candidates for high throughput screening efforts with small molecule libraries;[38,75] medium-sized molecules such as stabilized peptide helices may also effectively modulate these interactions. Several members in this class of PPIs have been successfully targeted.[3,19] The reason for this success could be due to the fact that the physical attributes shared by members of this class are reminiscent of traditional enzyme targets.

The interaction of the p53 activation domain with MDM2 is perhaps the most successfully targeted protein–protein interaction.[76–80] A number of inhibitors are currently in clinical trials as potential cancer therapeutics.[76] The p53 AD adopts a helical conformation to target MDM2 with three hydrophobic hot spot residues on successive helical turns.[69] Successful synthetic analogs mimic two or all three of these residues.[70,77] The three hot spots lie close in space to each other with very large average alanine mutagenesis, $\Delta\Delta G_{avg}$ ~3.5 kcal/mol, and ΔSASA values (Table 1). The interactions of Bcl-2 family anti-apoptotic proteins with the pro-apoptotic BH3 domains[81] provide alanine scan and ΔSASA values of similarly high magnitude have also been successfully targeted with small molecules[82–84] and stabilized helices.[50,85] Realization of potent inhibitors for these interactions suggests that complexes that feature a similar density of hot spot may also be targeted effectively. A full set of such complexes has been reported.[31] Table 1 lists a few examples, with $\Delta\Delta G$ and ΔSASA values and relative positioning of hot spots, that fit our rubric for *cleft* interfaces.

3.2. Extended helical interfaces

Protein–protein interactions that involve discontinuous interaction surfaces with hot spot residues distributed over large contact areas are classified in this category. These PPIs are especially challenging for small molecule inhibitors but may be amenable to disruption by larger molecules such as stabilized helices and peptide foldamers. A full list of *extended helical interfaces* in the PDB has also been reported and select examples are shown in Table 1.[31]

The entry of HIV-1 into host cells requires formation of a coiled-coil bundle consisting of gp41 N-terminal and C-terminal helices.[86–89] Design of small molecules that target this interaction with high affinity and specificity has been challenging;[90] however, potent inhibitors derived from peptide and β-peptide foldamers have been reported,[53,55,91–94] in keeping with the broad distribution of hot spot residues at this interface.[95] Similarly, attempts to target the interaction of Ras and SOS with small molecules had been largely unsuccessful because two key residues on a Sos helix that contacts Ras are located four helical turns away from each other.[96,97] A stabilized helix that spans this length and



Figure 3. (a) Positioning of side-chain residues on a canonical α-helix. (b–d) Examples of protein complexes with hot spot residues on one face, two faces, and three faces. (b) *Yersinia pestis* YopN/TyeA complex, PDB code 1XL3; (c) ligand-binding domain (LBD) of the retinoid X receptor/coactivator complex (PDB code 1XIU); (d) *Escherichia coli* sigma factor/anti-sigma RseA complex, PDB code 1OR7.

encompasses key hot spot residues was recently developed as the first direct inhibitor of this complex formation,[52] and regulator of the Ras signaling pathway.[98] Recent efforts in fragment screening suggest that small molecules that target an allosteric site on Ras may be designed to modulate activity of this therapeutically important target.[99,100]

4. Array of hot spots on interfacial α-helices

Based on the relative density of hot spots, the helical interfaces may be classified as *cleft* or *extended* as discussed above, allowing judicious design of inhibitors or screening strategies. As a next step, rational design of general classes of helix mimics as inhibitors requires mimicry of hot spot positioning on different helical faces. Examination of 480 interfacial helices with high alanine mutagenesis values, that is, $\Delta\Delta G_{avg} \geqslant 2$ kcal/mol, provides an indication of the distribution of hot spots on interfacial helices.[32] Roughly 60% of helical interfaces in this dataset feature helices with hot spot residues on one face of the helix, a third of the complexes utilize helices with hot spots on two faces and roughly 10% require all three faces for interaction with the target protein partner.[32] Examples of protein complexes with hot spot residues on one face, two faces and three faces are shown in Figure 3.

Several different synthetic strategies for helix mimicry have been reported.[10,11,13] These include design of non-peptidic helix mimetics, constrained helices and foldamers that display protein-like functionality. Each of these strategies offers different advantages. The small molecules potentially excel at bioavailability, while the larger molecules offer additional contacts for enhanced specificity. Helical peptides and foldamers also provide ready access to scaffolds capable of displaying multiple hot spots on all three faces.[32] We hypothesize that interfaces that contain a cluster of hot spot residues on the same face of the helix are well suited for small molecules. There are >200 such complexes in the current PDB, providing an attractive opportunity for design of new therapeutics.

5. Conclusions

Mimicry of protein secondary structures has been a long-standing goal of bioorganic and medicinal chemists. Evaluation of protein complexes suggests that interfaces where the hot spot functionality is localized on secondary structures may be inhibited through rational design of peptidic and nonpeptidic scaffolds that feature key functional groups in the desired conformation. We have undertaken a comprehensive study to locate every helical protein–protein interaction in the Protein Data Bank. Computational analysis of these complexes allows prediction of interfaces that may be inhibited by small molecules because the hot spot residues are clustered in a small region or by larger molecules because the hot spots are distributed over a bigger area. We expect similar studies to facilitate future design of PPI inhibitors as new classes of therapeutics.

Acknowledgments

We thank the National Institutes of Health (GM073943) and the National Science Foundation (CHE-1151554) for financial support. B.N.B. thanks New York University for the Dean's Dissertation Fellowship.

References and notes

1. Morelli, X.; Bourgeas, R.; Roche, P. *Curr. Opin. Chem. Biol.* **2011**, *15*, 475.
2. Thangudu, R. R.; Bryant, S. H.; Panchenko, A. R.; Madej, T. *J. Mol. Biol.* **2012**, *415*, 443.
3. Wells, J. A.; McClendon, C. L. *Nature* **2007**, *1001*, 450.
4. Wanner, J.; Fry, D. C.; Peng, Z.; Roberts, J. *Future Med. Chem.* **2011**, *3*, 2021.
5. Hopkins, A. L.; Groom, C. R. *Nat. Rev. Drug Disc.* **2002**, *1*, 727.
6. Drahl, C.; Cravatt, B. F.; Sorensen, E. J. *Angew. Chem., Int. Ed.* **2005**, *44*, 5788.
7. Babine, R. E.; Bender, S. L. *Chem. Rev.* **1997**, *97*, 1359.
8. Laskowski, R. A.; Luscombe, N. M.; Swindells, M. B.; Thornton, J. M. *Protein Sci.* **1996**, *5*, 2438.
9. Dundas, J.; Adamian, L.; Liang, J. *J. Mol. Biol.* **2011**, *406*, 713.
10. Garner, J.; Harding, M. M. *Org. Biomol. Chem.* **2007**, *5*, 3577.
11. Edwards, T. A.; Wilson, A. J. *Amino Acids* **2011**, *41*, 743.
12. Goodman, C. M.; Choi, S.; Shandler, S.; DeGrado, W. F. *Nat. Chem. Biol.* **2007**, *3*, 252.
13. Henchey, L. K.; Jochim, A. L.; Arora, P. S. *Curr. Opin. Chem. Biol.* **2008**, *12*, 692.
14. Toogood, P. L. *J. Med. Chem.* **2002**, *45*, 1543.
15. Erlanson, D. A.; Wells, J. A.; Braisted, A. C. *Annu. Rev. Biophys. Biomol. Struct.* **2004**, *33*, 199.
16. Arkin, M. R.; Wells, J. A. *Nat. Rev. Drug Disc.* **2004**, *3*, 301.
17. Meireles, L. M.; Mustata, G. *Curr. Top. Med. Chem.* **2011**, *11*, 248.
18. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. *J. Med. Chem.* **2008**, *51*, 3661.
19. Hajduk, P. J.; Greer, J. *Nat. Rev. Drug Disc.* **2007**, *6*, 211.
20. Tan, D. S. *Nat. Chem. Biol.* **2005**, *1*, 74.
21. Terrett, N. K. *Drug Discovery Today* **2010**, *7*, e97.
22. Herman, R. E.; Badders, D.; Fuller, M.; Makienko, E. G.; Houston, M. E.; Quay, S. C.; Johnson, P. H. *J. Biol. Chem.* **2007**, *282*, 9813.
23. Hu, B.; Gilkes, D. M.; Chen, J. *Cancer Res.* **2007**, *67*, 8810.
24. Gemperli, A. C.; Rutledge, S. E.; Maranda, A.; Schepartz, A. *J. Am. Chem. Soc.* **2005**, *127*, 1596.
25. Clackson, T.; Wells, J. A. *Science* **1995**, *267*, 383.
26. Keskin, O.; Gursoy, A.; Ma, B.; Nussinov, R. *Chem. Rev.* **2008**, *108*, 1225.
27. Bogan, A. A.; Thorn, K. S. *J. Mol. Biol.* **1998**, *280*, 1.
28. Moreira, I. S.; Fernandes, P. A.; Ramos, M. J. *Proteins* **2007**, *68*, 803.
29. Kortemme, T.; Baker, D. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 14116.
30. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. *Nucleic Acids Res.* **2000**, *28*, 235.
31. Jochim, A. L.; Arora, P. S. *ACS Chem. Biol.* **2010**, *5*, 919.
32. Bullock, B. N.; Jochim, A. L.; Arora, P. S. *J. Am. Chem. Soc.* **2011**, *133*, 14220.
33. Koes, D. R.; Camacho, C. J. *Bioinformatics* **2012**, *28*, 784.
34. Bourgeas, R.; Basse, M. J.; Morelli, X.; Roche, P. *PLoS One* **2010**, *5*, e9598.
35. Henrich, S.; Salo-Ahen, O. M.; Huang, B.; Rippmann, F. F.; Cruciani, G.; Wade, R. C. *J. Mol. Recognit.* **2010**, *23*, 209.
36. Reynes, C.; Host, H.; Camproux, A. C.; Laconde, G.; Leroux, F.; Mazars, A.; Deprez, B.; Fahraeus, R.; Villoutreix, B. O.; Sperandio, O. *PLoS Comput Biol* **2010**, *6*, e1000695.
37. Nayal, M.; Honig, B. *Proteins* **2006**, *63*, 892.
38. Higueruelo, A. P.; Schreyer, A.; Bickerton, G. R.; Pitt, W. R.; Groom, C. R.; Blundell, T. L. *Chem. Biol. Drug. Des.* **2009**, *74*, 457.
39. Davis, F. P.; Sali, A. *PLoS Comput. Biol.* **2010**, *6*, e1000668.
40. Jochim, A. L.; Arora, P. S. *Mol. Biosyst.* **2009**, *5*, 924.
41. Hammond, M. C.; Harris, B. Z.; Lim, W. A.; Bartlett, P. A. *Chem. Biol.* **2006**, *13*, 1247.
42. Khasanova, T. V.; Khakshoor, O.; Nowick, J. S. *Org. Lett.* **2008**, *10*, 5293.
43. Loughlin, W. A.; Tyndall, J. D. A.; Glenn, M. P.; Fairlie, D. P. *Chem. Rev.* **2004**, *104*, 6085.
44. Smith, A. B.; Keenan, T. P.; Holcomb, R. C.; Sprengeler, P. A.; Guzman, M. C.; Wood, J. L.; Carroll, P. J.; Hirschmann, R. *J. Am. Chem. Soc.* **1992**, *114*, 10672.
45. Angelo, N. G.; Arora, P. S. *J. Am. Chem. Soc.* **2005**, *127*, 17134.
46. Angelo, N. G.; Arora, P. S. *J. Org. Chem.* **2007**, *72*, 7963.
47. Ko, E.; Liu, J.; Burgess, K. *Chem. Soc. Rev.* **2011**, *40*, 4411.
48. Ko, E.; Liu, J.; Perez, L. M.; Lu, G.; Schaefer, A.; Burgess, K. *J. Am. Chem. Soc.* **2010**, *133*, 462.
49. Moellering, R. E.; Cornejo, M.; Davis, T. N.; Del Bianco, C.; Aster, J. C.; Blacklow, S. C.; Kung, A. L.; Gilliland, D. G.; Verdine, G. L.; Bradner, J. E. *Nature* **2009**, *462*, 182.
50. Walensky, L. D.; Kung, A. L.; Escher, I.; Malia, T. J.; Barbuto, S.; Wright, R. D.; Wagner, G.; Verdine, G. L.; Korsmeyer, S. J. *Science* **2004**, *305*, 1466.
51. Stewart, M. L.; Fire, E.; Keating, A. E.; Walensky, L. D. *Nat. Chem. Biol.* **2010**, *6*, 595.
52. Patgiri, A.; Yadav, K. K.; Arora, P. S.; Bar-Sagi, D. *Nat. Chem. Biol.* **2011**, *7*, 585.
53. Horne, W. S.; Johnson, L. M.; Ketas, T. J.; Klasse, P. J.; Lu, M.; Moore, J. P.; Gellman, S. H. *Proc. Natl. Acad. Sci. U.S.A.* **2009**, *106*, 14751.
54. Harrison, R. S.; Shepherd, N. E.; Hoang, H. N.; Ruiz-Gomez, G.; Hill, T. A.; Driver, R. W.; Desai, V. S.; Young, P. R.; Abbenante, G.; Fairlie, D. P. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, *107*, 11686.
55. Stephens, O. M.; Kim, S.; Welch, B. D.; Hodsdon, M. E.; Kay, M. S.; Schepartz, A. *J. Am. Chem. Soc.* **2005**, *127*, 13126.
56. Cummings, C. G.; Hamilton, A. D. *Curr. Opin. Chem. Biol.* **2010**, *14*, 341.
57. Tosovska, P.; Arora, P. S. *Org. Lett.* **2010**, *12*, 1588.
58. Lee, J. H.; Zhang, Q.; Jo, S.; Chai, S. C.; Oh, M.; Im, W.; Lu, H.; Lim, H. S. *J. Am. Chem. Soc.* **2011**, *133*, 676.
59. Plante, J. P.; Burnley, T.; Malkova, B.; Webb, M. E.; Warriner, S. L.; Edwards, T. A.; Wilson, A. J. *Chem. Commun.* **2009**, 5091.
60. Shaginian, A.; Whitby, L. R.; Hong, S.; Hwang, I.; Farooqi, B.; Searcey, M.; Chen, J.; Vogt, P. K.; Boger, D. L. *J. Am. Chem. Soc.* **2009**, *131*, 5564.
61. Patgiri, A.; Jochim, A. L.; Arora, P. S. *Acc. Chem. Res.* **2008**, *41*, 1289.
62. Schafmeister, C. E.; Po, J.; Verdine, G. L. *J. Am. Chem. Soc.* **2000**, *122*, 5891.

63. Shepherd, N. E.; Hoang, H. N.; Abbenante, G.; Fairlie, D. P. *J. Am. Chem. Soc.* **2005**, *127*, 2974.
64. Cunningham, B. C.; Wells, J. A. *Science* **1989**, *1081*, 244.
65. Kortemme, T.; Kim, D. E.; Baker, D. *Sci. STKE* **2004**, *2004*, pl2.
66. Koes, D. R.; Camacho, C. J. *Nucleic Acids Res.* **2012**, *40*, W387.
67. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. *Adv. Drug Delivery Rev.* **1997**, *23*, 3.
68. Hann, M. M.; Keseru, G. M. *Nat. Rev. Drug Disc.* **2012**, *11*, 355.
69. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. *Science* **1996**, *274*, 948.
70. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. *Science* **2004**, *303*, 844.
71. Alex, A.; Millan, D. S.; Perez, M.; Wakenhut, F.; Whitlock, G. A. *MedChemComm* **2011**, *2*, 669.
72. White, T. R.; Renzelman, C. M.; Rand, A. C.; Rezai, T.; McEwen, C. M.; Gelev, V. M.; Turner, R. A.; Linington, R. G.; Leung, S. S. F.; Kalgutkar, A. S.; Bauman, J. N.; Zhang, Y.; Liras, S.; Price, D. A.; Mathiowetz, A. M.; Jacobson, M. P.; Lokey, R. S. *Nat. Chem. Biol.* **2011**, *7*, 810.
73. Arora, P. S.; Ansari, A. Z. *Nature* **2009**, *462*, 171.
74. Henchey, L. K.; Kushal, S.; Dubey, R.; Chapman, R. N.; Olenyuk, B. Z.; Arora, P. S. *J. Am. Chem. Soc.* **2010**, *132*, 941.
75. Welsch, M. E.; Snyder, S. A.; Stockwell, B. R. *Curr. Opin. Chem. Biol.* **2010**, *14*, 347.
76. Cheok, C. F.; Verma, C. S.; Baselga, J.; Lane, D. P. *Nat. Rev. Clin. Oncol.* **2011**, *8*, 25.
77. Shangary, S.; Wang, S. *Annu. Rev. Pharmacol. Toxicol.* **2009**, *49*, 223.
78. Vassilev, L. T. *Trends Mol. Med.* **2007**, *13*, 23.
79. Chene, P. *Nat. Rev. Cancer* **2003**, *3*, 102.
80. Bernal, F.; Tyler, A. F.; Korsmeyer, S. J.; Walensky, L. D.; Verdine, G. L. *J. Am. Chem. Soc.* **2007**, *129*, 2456.
81. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R. P.; Harlan, J. E.; Eberstadt, M.; Yoon, H. S.; Shuker, S. B.; Chang, B. S.; Minn, A. J.; Thompson, C. B.; Fesik, S. W. *Science* **1997**, *275*, 983.
82. Gavathiotis, E.; Reyna, D. E.; Bellairs, J. A.; Leshchiner, E. S.; Walensky, L. D. *Nat. Chem. Biol.* **2012**, *8*, 639.
83. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. *Nature* **2005**, *435*, 677.
84. Vogler, M.; Dinsdale, D.; Dyer, M. J. S.; Cohen, G. M. *Cell Death Differ.* **2008**, *16*, 360.
85. Stewart, M. L.; Fire, E.; Keating, A. E.; Walensky, L. D. *Nat. Chem. Biol.* **2010**, *6*, 595.
86. Eckert, D. M.; Kim, P. S. *Annu. Rev. Biochem.* **2001**, *70*, 777.
87. Weissenhorn, W.; Dessen, A.; Harrison, S. C.; Skehel, J. J.; Wiley, D. C. *Nature* **1997**, *387*, 426.
88. Tan, K.; Liu, J.; Wang, J.; Shen, S.; Lu, M. *Proc. Natl. Acad. Sci. U.S.A.* **1997**, *94*, 12303.
89. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. *Cell* **1997**, *89*, 263.
90. Pan, C.; Liu, S.; Jiang, S. *J. Formos Med. Assoc.* **2010**, *109*, 94.
91. Matthews, T.; Salgo, M.; Greenberg, M.; Chung, J.; DeMasi, R.; Bolognesi, D. *Nat. Rev. Drug Disc.* **2004**, *3*, 215.
92. Wang, D.; Lu, M.; Arora, P. S. *Angew. Chem., Int. Ed.* **1879**, *2008*, 47.
93. Sia, S. K.; Carr, P. A.; Cochran, A. G.; Malashkevich, V. N.; Kim, P. S. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 14664.
94. Ernst, J. T.; Kutzki, O.; Debnath, A. K.; Jiang, S.; Lu, H.; Hamilton, A. D. *Angew. Chem., Int. Ed.* **2002**, *41*, 278.
95. Johnson, L. M.; Horne, W. S.; Gellman, S. H. *J. Am. Chem. Soc.* **2011**, *133*, 10038.
96. Boriack-Sjodin, P. A.; Margarit, S. M.; Bar-Sagi, D.; Kuriyan, J. *Nature* **1998**, *394*, 337.
97. Hall, B. E.; Yang, S. S.; Boriack-Sjodin, P. A.; Kuriyan, J.; Bar-Sagi, D. *J. Biol. Chem.* **2001**, *276*, 27629.
98. Pylayeva-Gupta, Y.; Grabocka, E.; Bar-Sagi, D. *Nat. Rev. Cancer* **2011**, *11*, 761.
99. Maurer, T.; Garrenton, L. S.; Oh, A.; Pitts, K.; Anderson, D. J.; Skelton, N. J.; Fauber, B. P.; Pan, B.; Malek, S.; Stokoe, D.; Ludlam, M. J.; Bowman, K. K.; Wu, J.; Giannetti, A. M.; Starovasnik, M. A.; Mellman, I.; Jackson, P. K.; Rudolph, J.; Wang, W.; Fang, G. *Proc. Natl. Acad. Sci. U.S.A.* **2012**, *109*, 5299.
100. Sun, Q.; Burke, J. P.; Phan, J.; Burns, M. C.; Olejniczak, E. T.; Waterson, A. G.; Lee, T.; Rossanese, O. W.; Fesik, S. W. *Angew. Chem., Int. Ed.* **2012**, *51*, 6140.
101. Henchey, L. K.; Porter, J. R.; Ghosh, I.; Arora, P. S. *ChemBioChem* **2010**, *11*, 2104.
102. Kritzer, J. A.; Lear, J. D.; Hodsdon, M. E.; Schepartz, A. *J. Am. Chem. Soc.* **2004**, *126*, 9468.
103. Murray, J. K.; Gellman, S. H. *Biopolymers* **2007**, *88*, 657.
104. Fasan, R.; Dias, R. L. A.; Moehle, K.; Zerbe, O.; Vrijbloed, J. W.; Obrecht, D.; Robinson, J. A. *Angew. Chem., Int. Ed.* **2004**, *43*, 2109.
105. Yin, H.; Lee, G.-i.; Park, H. S.; Payne, G. A.; Rodriguez, J. M.; Sebti, S. M.; Hamilton, A. D. *Angew. Chem., Int. Ed.* **2005**, *44*, 2704.
106. Austin, R. J.; Ja, W. W.; Roberts, R. W. *J. Mol. Biol.* **2008**, *377*, 1406.
107. Millward, S. W.; Fiacco, S.; Austin, R. J.; Roberts, R. W. *ACS Chem. Biol.* **2007**, *2*, 625.
108. Bruncko, M.; Oost, T. K.; Belli, B. A.; Ding, H.; Joseph, M. K.; Kunzer, A.; Martineau, D.; McClellan, W. J.; Mitten, M.; Ng, S. C.; Nimmer, P. M.; Oltersdorf, T.; Park, C. M.; Petros, A. M.; Shoemaker, A. R.; Song, X.; Wang, X.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. *J. Med. Chem.* **2007**, *50*, 641.
109. Tse, C.; Shoemaker, A. R.; Adickes, J.; Anderson, M. G.; Chen, J.; Jin, S.; Johnson, E. F.; Marsh, K. C.; Mitten, M. J.; Nimmer, P.; Roberts, L.; Tahir, S. K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S. H.; Elmore, S. W. *Cancer Res.* **2008**, *68*, 3421.
110. Degterev, A.; Lugovskoy, A.; Cardone, M.; Mulley, B.; Wagner, G.; Mitchison, T.; Yuan, J. *Nat. Cell Biol.* **2001**, *3*, 173.
111. Yang, B.; Liu, D.; Huang, Z. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 1403.
112. Wang, D.; Liao, W.; Arora, P. S. *Angew. Chem., Int. Ed.* **2005**, *44*, 6525.
113. Kutzki, O.; Park, H. S.; Ernst, J. T.; Orner, B. P.; Yin, H.; Hamilton, A. D. *J. Am. Chem. Soc.* **2002**, *124*, 11838.
114. Lee, J.; Kim, K.-H.; Jeong, S. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 4203.
115. Bramson, H. N.; Corona, J.; Davis, S. T.; Dickerson, S. H.; Edelstein, M.; Frye, S. V., ; Gampe, R. T., Jr.; Harris, P. A.; Hassell, A.; Holmes, W. D.; Hunter, R. N.; Lackey, K. E.; Lovejoy, B.; Luzzio, M. J.; Montana, V.; Rocque, W. J.; Rusnak, D.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. *J. Med. Chem.* **2001**, *44*, 4339.
116. Frey, G.; Rits-Volloch, S.; Zhang, X. Q.; Schooley, R. T.; Chen, B.; Harrison, S. C. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 13938.
117. Ferrer, M.; Kapoor, T. M.; Strassmaier, T.; Weissenhorn, W.; Skehel, J. J.; Oprian, D.; Schreiber, S. L.; Wiley, D. C.; Harrison, S. C. *Nat. Struct. Biol.* **1999**, *6*, 953.